Half-Year 2022 Financial and Clinical Trials Update

Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Metastatic and/or recurrent PD-L1+ cervical cancer (CC) Neoadjuvant and adjuvant NSCLC Phase/study # of patients Phase II SKYSCRAPER-04 N=172 ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq Design ■ Objective response rate Primary endpoint FPI Q2 2020 Status CT Identifier NCT04300647 NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1 Phase II SKYSCRAPER-05 N=82 1L non-squamous NSCLC Phase II/III SKYSCRAPER-06 N=500 " ■ ARM A: (PD-L1 high) neoadjuvant tiragolumab plus Tecentriq followed by adjuvant tiragolumab plus Tecentriq or adjuvant chemotherapy ■ ARM B: (PD-L1 all-comers) neoadjuvant tiragolumab plus Tecentriq plus chemo followed by adjuvant tiragolumab plus Tecentriq ■ Pathologic complete response, major pathological response and safety " FPI Q2 2021 " ARM A: Tiragolumab plus Tecentriq plus pemetrexed plus chemo followed by maintenance tiragolumab plus Tecentriq plus pemetrexed ARM B: Placebo plus pembrolizumab plus pemetrexed plus chemo followed by maintenance placebo plus pembrolizumab plus pemetrexed ■ Objective response rate, progression-free survival and overall survival ☐ FPI Q4 2020 NCT04832854 NCT04619797 Roche 128 Oncology

View entire presentation